5 results about "Romidepsin" patented technology

The invention relates to the technical field of gene engineering, in particular to an HDR enhancer for improving cell homologous recombination efficiency and application of the HDR enhancer, and the HDR enhancer for improving the cell homologous recombination efficiency comprises an inhibitor of a non-homologous end connection repair pathway and an intracellular homologous recombination accelerant; the inhibitors of the non-homologous end connection repair pathway are SCR-7 and M3814, the intracellular homologous recombination accelerators are L755507 and Romidepsin, the four agents synergistically target an NHEJ signal pathway, the cell cycle, chromatin structure opening and HDR signal pathway are regulated and controlled at the same time, and the problem that an existing reagent for improving the cell homologous recombination efficiency is insufficient in synergistic effect is solved.

The application provides application of a ZNF652 gene as a marker in preparation of a kit for evaluating cancer occurrence risk and / or prognosis, wherein the ZNF652 gene as the marker comprises transcription of ZNF652 and / or loss of heterozygosity (LOH) of ZNF652. Further provided is use of a ZNF652 gene expression detection reagent in preparation of a kit for guiding anti-PD-L1 immunotherapy and guiding combination use of an anti-PD-L1 antibody. Further provided is use of an HDAC inhibitor romidepsin combined with an anti-PD-L1 antibody in preparation of a breast cancer treatment drug. The application provides an important theoretical basis for evaluating occurrence risk, treatment and prognosis of clinical triple-negative breast cancer.

Provided are compositions that include histone deacetylase (HDAC) inhibitors encapsulated in and / or otherwise associated with detectable nanoparticles, and methods for using the same in medical and veterinary applications including but not limited to treating diseases, disorders, and / or conditions associated with sensitivity to HDAC inhibitors; inhibiting the growth, proliferation, and / or metastasis of a tumor and / or a cancer associated with sensitivity to HDAC inhibitors, and for treating inflammatory and / or an autoimmune diseases, disorders, and / or conditions associated with sensitivity to HDAC inhibitors. Also provided are methods for imaging cells, tissues, organs, and / or other targets in subject.

The present application belongs to the field of microbial genetic engineering technology, and particularly relates to tumor-targeting drug-producing engineering strains and a construction method and application thereof. The present application discloses a series of tumor-targeting drug-producing engineering strains, which can produce the anticancer drug romidepsin in situ in a tumor, can heterologously express romidepsin, and can produce romidepsin in situ in a tumor of a tumor-bearing small animal and has the activity of inhibiting tumor growth. That is, the present application provides a series of Escherichia coli Nissle 1917 recombinant strains, which are expected to become an anticancer live bacterial drug and will be applied to the clinic in the future, and therefore have good practical application value.

The present invention includes a method to increase romidepsin concentration in a bacteria fermentation media. Romidepsin concentration in a fermentation is increased by adding, for example, copper sulfate. The end resulting romidepsin concentration is increased by at least about two fold as compare to fermentation without copper sulfate.